Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA – Get Free Report) CEO Sanj Patel sold 92,891 shares of Kiniksa Pharmaceuticals International stock in a transaction that occurred on Friday, October 30th. The shares were sold at an average price of $93.12, for a total value of $8,650,009.92. Following the sale, the chief executive officer owned 905,933 shares in the company, valued at $84,360,480.96. This represents a 9.30% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Kiniksa Pharmaceuticals International Stock Up 2.7%
Shares of KNSA stock opened at $93.29 on Wednesday. The business’s fifty day moving average is $79.67 and its 200 day moving average is $60.56. The stock has a market cap of $7.28 billion, a price-to-earnings ratio of 71.76 and a beta of 0.07. Kiniksa Pharmaceuticals International, plc has a twelve month low of $37.02 and a twelve month high of $98.48.
Kiniksa Pharmaceuticals International (NASDAQ:KNSA – Get Free Report) last announced its quarterly earnings data on Tuesday, October 27th. The company reported $0.56 EPS for the quarter, beating the consensus estimate of $0.37 by $0.19. Kiniksa Pharmaceuticals International had a return on equity of 17.27% and a net margin of 11.58%. The business had revenue of $285.97 million during the quarter, compared to analyst estimates of $260.66 million. Equities research analysts expect that Kiniksa Pharmaceuticals International, plc will post 1.30 earnings per share for the current fiscal year.
Wall Street Analysts Forecast Growth
A number of research analysts recently issued reports on the stock. Citigroup lifted their price target on shares of Kiniksa Pharmaceuticals International from $60.00 to $100.00 and gave the company a “buy” rating in a research report on Wednesday, July 29th. Weiss Ratings cut shares of Kiniksa Pharmaceuticals International from a “buy (b-)” rating to a “hold (c-)” rating in a report on Wednesday, October 28th. Wells Fargo & Company raised their target price on shares of Kiniksa Pharmaceuticals International from $87.00 to $110.00 and gave the company an “overweight” rating in a research note on Wednesday, October 28th. Zacks Research lowered shares of Kiniksa Pharmaceuticals International from a “strong-buy” rating to a “hold” rating in a report on Thursday, July 30th. Finally, Canaccord Genuity Group lifted their target price on shares of Kiniksa Pharmaceuticals International from $64.00 to $98.00 and gave the company a “buy” rating in a report on Wednesday, July 29th. Seven analysts have rated the stock with a Buy rating and two have issued a Hold rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $100.57.
Check Out Our Latest Report on KNSA
Kiniksa Pharmaceuticals International News Roundup
Here are the key news stories impacting Kiniksa Pharmaceuticals International this week:
- Negative Sentiment: Across October 30 and November 2, CAO Michael Megna, COO Ross Moat, CFO Mark Ragosa and insider John Paolini reported sales totaling about 272,600 shares, worth approximately $25.4 million. The selling could weigh on sentiment or temper the stock’s recent momentum. However, each transaction was made under a pre-arranged Rule 10b5-1 plan, so it is not necessarily a response to new company developments. Megna SEC filing Moat SEC filing Paolini SEC filing Ragosa SEC filing
Hedge Funds Weigh In On Kiniksa Pharmaceuticals International
Several institutional investors and hedge funds have recently modified their holdings of the stock. Rubric Capital Management LP raised its position in shares of Kiniksa Pharmaceuticals International by 12.7% in the 1st quarter. Rubric Capital Management LP now owns 3,750,000 shares of the company’s stock worth $180,562,000 after purchasing an additional 421,347 shares during the last quarter. Pictet Asset Management Holding SA boosted its stake in Kiniksa Pharmaceuticals International by 41.3% in the 3rd quarter. Pictet Asset Management Holding SA now owns 860,228 shares of the company’s stock worth $64,182,000 after purchasing an additional 251,578 shares in the last quarter. Dimensional Fund Advisors LP grew its position in Kiniksa Pharmaceuticals International by 18.8% during the 1st quarter. Dimensional Fund Advisors LP now owns 811,922 shares of the company’s stock valued at $39,086,000 after purchasing an additional 128,417 shares during the last quarter. Spruce Street Capital LP grew its position in Kiniksa Pharmaceuticals International by 75.0% during the 1st quarter. Spruce Street Capital LP now owns 761,063 shares of the company’s stock valued at $36,645,000 after purchasing an additional 326,081 shares during the last quarter. Finally, Bank of America Corp DE grew its position in Kiniksa Pharmaceuticals International by 220.9% during the 1st quarter. Bank of America Corp DE now owns 735,940 shares of the company’s stock valued at $35,436,000 after purchasing an additional 506,576 shares during the last quarter. 53.95% of the stock is currently owned by institutional investors.
About Kiniksa Pharmaceuticals International
Kiniksa Pharmaceuticals International plc is a commercial-stage biopharmaceutical company focused on developing and commercializing therapies for patients with serious and often under-treated immunological diseases. The company’s research and development efforts are centered on targeting specific pathways involved in inflammation and immune-system dysfunction.
Kiniksa’s principal commercial product is ARCALYST (rilonacept), an interleukin-1 inhibitor. In the United States, ARCALYST is approved for reducing the risk of recurrence in patients with recurrent pericarditis and for the treatment of cryopyrin-associated periodic syndromes, including familial cold autoinflammatory syndrome and Muckle-Wells syndrome, in eligible patients.
The company also maintains a pipeline of investigational medicines designed to address autoimmune and inflammatory conditions.
Featured Stories
- Five stocks we like better than Kiniksa Pharmaceuticals International
- Marriott’s Earnings Beat Shows Why It’s More Than a Bet on Travel Demand
- Franklin Templeton’s New ETFs Turn Stock Dividends Into Bitcoin—What’s the Catch?
- Apple’s Earnings Beat Comes With a Catch for Investors Heading Into the Holidays
- Palantir’s $2.3 Billion Quarter Puts Its Premium Valuation to the Test
Receive News & Ratings for Kiniksa Pharmaceuticals International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kiniksa Pharmaceuticals International and related companies with MarketBeat.com's FREE daily email newsletter.
